Limits...
Sustained Improvement of Arterial Stiffness and Blood Pressure after Long-Term Rosuvastatin Treatment in Patients with Inflammatory Joint Diseases: Results from the RORA-AS Study.

Ikdahl E, Rollefstad S, Hisdal J, Olsen IC, Pedersen TR, Kvien TK, Semb AG - PLoS ONE (2016)

Bottom Line: AIx, aPWV, sBP and dBP were significantly reduced from baseline to study end.We have shown for the first time that long-term intensive lipid lowering with rosuvastatin improved arterial stiffness and induced a clinically significant BP reduction in patients with IJD.These improvements were linearly correlated and may represent novel insight into the pleiotropic effects by statins.

View Article: PubMed Central - PubMed

Affiliation: Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.

ABSTRACT

Objective: Patients with inflammatory joint diseases (IJD) have a high prevalence of hypertension and increased arterial stiffness. The aim of the present study was to evaluate the effect of long-term rosuvastatin treatment on arterial stiffness, measured by augmentation index (AIx) and aortic pulse wave velocity (aPWV), and blood pressure (BP) in IJD patients with established atherosclerosis.

Methods: Eighty-nine statin naïve IJD patients with carotid atherosclerotic plaque(s) (rheumatoid arthritis n = 55, ankylosing spondylitis n = 23, psoriatic arthritis n = 11) received rosuvastatin for 18 months to achieve low-density lipoprotein cholesterol goal ≤1.8 mmol/L. Change in AIx (ΔAIx), aPWV (ΔaPWV), systolic BP (ΔsBP) and diastolic BP (ΔdBP) from baseline to study end was assessed by paired samples t-tests. Linear regression was applied to evaluate associations between cardiovascular disease (CVD) risk factors, rheumatic disease specific variables and medication, and ΔAIx, ΔaPWV, ΔsBP and ΔdBP.

Results: AIx, aPWV, sBP and dBP were significantly reduced from baseline to study end. The mean (95%CI) changes were: ΔAIx: -0.34 (-0.03, -0.65)% (p = 0.03), ΔaPWV: -1.69 (-0.21, -3.17) m/s2 (p = 0.03), ΔsBP: -5.27 (-1.61, -8.93) mmHg (p = 0.004) and ΔdBP -2.93 (-0.86, -5.00) mmHg (p = 0.01). In linear regression models, ∆aPWV was significantly correlated with ΔsBP and ΔdBP (for all: p<0.001).

Conclusions: There is an unmet need of studies evaluating CVD prevention in IJD patients. We have shown for the first time that long-term intensive lipid lowering with rosuvastatin improved arterial stiffness and induced a clinically significant BP reduction in patients with IJD. These improvements were linearly correlated and may represent novel insight into the pleiotropic effects by statins.

Trial registration: ClinicalTrials.gov NCT01389388.

No MeSH data available.


Related in: MedlinePlus

Change in aortic pulse wave velocity (aPWV) and augmentation index (AIx) after 18 months rosuvastatin therapy.SE: standard error of the mean, SD: standard deviation of the mean.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4836743&req=5

pone.0153440.g002: Change in aortic pulse wave velocity (aPWV) and augmentation index (AIx) after 18 months rosuvastatin therapy.SE: standard error of the mean, SD: standard deviation of the mean.

Mentions: Arterial stiffness improved significantly after 18 months of intensive lipid lowering with rosuvastatin (Fig 2). The mean (95% confidence interval [CI]) reduction in AIx and aPWV was -0.34 (-0.03, -0.65) % and -1.69 (95% CI: -0.21, -3.17) m/s2, respectively. Brachial BP was also significantly improved as the mean (SD) sBP was reduced by -5.27 (95% CI: -1.61, -8.93) mmHg and dBP was reduced by -2.93 (-0.86, -5.00) mmHg (Fig 3). The trends towards decreasing AIx, PWV, sBP and dBP were present in all diagnose groups (S1 Table).


Sustained Improvement of Arterial Stiffness and Blood Pressure after Long-Term Rosuvastatin Treatment in Patients with Inflammatory Joint Diseases: Results from the RORA-AS Study.

Ikdahl E, Rollefstad S, Hisdal J, Olsen IC, Pedersen TR, Kvien TK, Semb AG - PLoS ONE (2016)

Change in aortic pulse wave velocity (aPWV) and augmentation index (AIx) after 18 months rosuvastatin therapy.SE: standard error of the mean, SD: standard deviation of the mean.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4836743&req=5

pone.0153440.g002: Change in aortic pulse wave velocity (aPWV) and augmentation index (AIx) after 18 months rosuvastatin therapy.SE: standard error of the mean, SD: standard deviation of the mean.
Mentions: Arterial stiffness improved significantly after 18 months of intensive lipid lowering with rosuvastatin (Fig 2). The mean (95% confidence interval [CI]) reduction in AIx and aPWV was -0.34 (-0.03, -0.65) % and -1.69 (95% CI: -0.21, -3.17) m/s2, respectively. Brachial BP was also significantly improved as the mean (SD) sBP was reduced by -5.27 (95% CI: -1.61, -8.93) mmHg and dBP was reduced by -2.93 (-0.86, -5.00) mmHg (Fig 3). The trends towards decreasing AIx, PWV, sBP and dBP were present in all diagnose groups (S1 Table).

Bottom Line: AIx, aPWV, sBP and dBP were significantly reduced from baseline to study end.We have shown for the first time that long-term intensive lipid lowering with rosuvastatin improved arterial stiffness and induced a clinically significant BP reduction in patients with IJD.These improvements were linearly correlated and may represent novel insight into the pleiotropic effects by statins.

View Article: PubMed Central - PubMed

Affiliation: Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.

ABSTRACT

Objective: Patients with inflammatory joint diseases (IJD) have a high prevalence of hypertension and increased arterial stiffness. The aim of the present study was to evaluate the effect of long-term rosuvastatin treatment on arterial stiffness, measured by augmentation index (AIx) and aortic pulse wave velocity (aPWV), and blood pressure (BP) in IJD patients with established atherosclerosis.

Methods: Eighty-nine statin naïve IJD patients with carotid atherosclerotic plaque(s) (rheumatoid arthritis n = 55, ankylosing spondylitis n = 23, psoriatic arthritis n = 11) received rosuvastatin for 18 months to achieve low-density lipoprotein cholesterol goal ≤1.8 mmol/L. Change in AIx (ΔAIx), aPWV (ΔaPWV), systolic BP (ΔsBP) and diastolic BP (ΔdBP) from baseline to study end was assessed by paired samples t-tests. Linear regression was applied to evaluate associations between cardiovascular disease (CVD) risk factors, rheumatic disease specific variables and medication, and ΔAIx, ΔaPWV, ΔsBP and ΔdBP.

Results: AIx, aPWV, sBP and dBP were significantly reduced from baseline to study end. The mean (95%CI) changes were: ΔAIx: -0.34 (-0.03, -0.65)% (p = 0.03), ΔaPWV: -1.69 (-0.21, -3.17) m/s2 (p = 0.03), ΔsBP: -5.27 (-1.61, -8.93) mmHg (p = 0.004) and ΔdBP -2.93 (-0.86, -5.00) mmHg (p = 0.01). In linear regression models, ∆aPWV was significantly correlated with ΔsBP and ΔdBP (for all: p<0.001).

Conclusions: There is an unmet need of studies evaluating CVD prevention in IJD patients. We have shown for the first time that long-term intensive lipid lowering with rosuvastatin improved arterial stiffness and induced a clinically significant BP reduction in patients with IJD. These improvements were linearly correlated and may represent novel insight into the pleiotropic effects by statins.

Trial registration: ClinicalTrials.gov NCT01389388.

No MeSH data available.


Related in: MedlinePlus